These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 5969307

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Assessment of efficacy of a live oral poliovirus vaccine for virulent Sabin-like poliovirus 1 strains in Japan.
    Iwai M, Nakayama T, Matsuura K, Hasegawa S, Ando S, Obara M, Nagai Y, Yoshida H, Horie H.
    Acta Virol; 2006; 50(2):139-43. PubMed ID: 16808333
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Type I poliomyelitis epidemic in France and use of homotypic vaccine (Sabin I LSc 2 ab) by oral administration. II. Study of the results of vaccination. Characterization of the virus eliminated by the vaccines].
    Boué A, Drouhet V.
    Arch Gesamte Virusforsch; 1966; 18(1):59-71. PubMed ID: 4294187
    [No Abstract] [Full Text] [Related]

  • 25. [Poliomyelitic neutralizing antibodies in Senegal, their formation in subjects already immune and vaccinated with the Sabin virus].
    Barme M, Ceolin G.
    Bull Soc Med Afr Noire Lang Fr; 1967; 12(2):320-5. PubMed ID: 5606066
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Paralytic poliomyelitis caused by a vaccine-derived polio virus in an antibody-deficient Argentinean child.
    Hidalgo S, García Erro M, Cisterna D, Freire MC.
    Pediatr Infect Dis J; 2003 Jun; 22(6):570-2. PubMed ID: 12828159
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Worldwide eradication of poliomyelitis].
    Rasch G, Schreier E, Kiehl W, Kurth R.
    Wien Klin Wochenschr; 2001 Oct 30; 113(20-21):839-45. PubMed ID: 11732120
    [Abstract] [Full Text] [Related]

  • 33. [History and results of a campaign against poliomyelitis].
    Rotta C, Fiandaca S.
    Minerva Med; 1967 Aug 04; 58(61):2755-9. PubMed ID: 6049069
    [No Abstract] [Full Text] [Related]

  • 34. [Some questions of the theory of live vaccine and vaccination against poliomyelitis with Sabin vaccine].
    GINSBURG NN.
    Vopr Virusol; 1959 Aug 04; 4():620-4. PubMed ID: 13850246
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. USOL-D bac (type 3 poliovirus) vaccine studies.
    Bull World Health Organ; 1969 Aug 04; 40(2):295-300. PubMed ID: 5306547
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Poliomyelitis vaccines: an appraisal after 25 years.
    Melnick JL.
    Compr Ther; 1980 Jan 04; 6(1):6-14. PubMed ID: 7357844
    [No Abstract] [Full Text] [Related]

  • 39. Vaccination of adults with a British oral poliomyelitis vaccine prepared from Sabin strains.
    GOFFE A, POLLOCK TM, SHAND FL.
    Br Med J; 1961 Jul 29; 2(5247):272-5. PubMed ID: 13706303
    [No Abstract] [Full Text] [Related]

  • 40. Seroprevalence of anti-polio antibodies in a population 7 months to 39 years of age in Uruguay: Implications for future polio vaccination strategies.
    Pírez MC, Olivera I, Diabarboure H, Montano A, Barañano R, Badía F, Bonnet MC.
    Vaccine; 2009 May 05; 27(20):2689-94. PubMed ID: 19428880
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.